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MINIREVIEWS

Anti-integrin therapy for inflammatory bowel disease
Sung Chul Park, Yoon Tae Jeen

Abstract

Sung Chul Park, Division of Gastroenterology and Hepatology,
Department of Internal Medicine, Kangwon National University
School of Medicine, Chuncheon 24289, South Korea

In inflammatory bowel disease (IBD), tumor necro
sis factor plays an important role in mediating infla
mmation, but several other pathways are also involved
in eliciting an inflammatory response. One such
pathway is the invasion of the intestinal mucosa by
leukocytes. Leukocytes within the systemic circulation
move to sites of inflammation, and blocking this
pathway could be an important treatment strategy
for IBD. Anti-integrin therapy blocks the action of
integrin on the surface of circulating immune cells and
endothelial cell adhesion molecules, thereby inhibiting
the interactions between leukocytes and intestinal blood
vessels. Natalizumab, which acts on α4-integrin, was
the first such drug to be approved for Crohn’s disease,
but its use is limited due to the risk of progressive
multifocal leukoencephalopathy. Vedolizumab produces
few systemic adverse effects because it acts on guttrophic α4β7 integrin, and has been approved and is
being used to treat IBD. Currently, several anti-integrin
drugs, including etrolizumab, which acts on β7-integrin,
and PF-00547569, which targets mucosal addressin cell
adhesion molecule-1, are undergoing clinical trials and
the results are being closely watched.
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Core tip: Anti-integrin therapies have attracted attention
as new therapeutic agents in inflammatory bowel dis
ease. They inhibit the extravasation of leukocytes by
blocking the interaction between integrins on immune
cells and endothelial cell adhesion molecules. The use
of the first developed anti-integrin agent, natalizumab
is now limited due to the risk of progressive multifocal
leukoencephalopathy. However, vedolizumab which acts
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selectively on the gut has shown few adverse events
and is currently used in clinical practice. Newer antiintegrin drugs that act on different integrins-related
targets, such as AJM300, abrilumab, etrolizumab, and
PF-00547659 have also been developed and are in
clinical trials.

tokines define and regulate various aspects of the infla
mmatory response and play an important role in the
pathogenesis of IBD including Crohn’s disease (CD)
and ulcerative colitis (UC), with the former mediated
by type 1 T helper cells (TH1) and TH17, and the latter
reportedly caused by an abnormal TH2 response. The
immunopathogenesis of IBD is made more complex
by imbalances in different T cell subsets, such as
regulatory T cells, natural killer T cells, and TH9, as
well as the interactions between these cell populations.
Ultimately, the production of numerous cytokines is
disturbed. These cytokines include the well-known
TNF-α as well as IL-1β, IL-6, IL-8, IL-10, IL-12, IL-17,
[3,6]
IL-23, and transforming growth factor-α .
The use of TNF antagonists showed that just blocking
a single cytokine could be sufficient to induce significant
clinical remission. Until recently, in moderate-to-severe
active IBD patients, especially if initial treatment with
systemic corticosteroids or immunomodulators failed,
anti-TNF agents were the only remaining treatment
option.
Inspired by the treatment outcomes of the first
generation anti-TNF agent infliximab, next-generation
TNF antagonists, such as adalimumab, golimumab,
and certolizumab pegol, were introduced for the treat
ment of IBD, drastically changing this treatment field;
however, even these drugs did not show an effect in
all IBD patients. Specifically, although reports differ
slightly, anti-TNF agents produce primary non-response
[7]
(PNR) in approximately 10%-30% of patients . Several
factors have been suggested as causes of PNR. One
known cause of PNR is that TNF is not a major factor in
the development of inflammation in some patients, and
therefore, there is an increased need for drugs with new
[8]
mechanisms .
Although anti-TNF agents show an initial effect,
secondary non-response or loss of response (LOR) is
[7,9]
seen in 23%-46% . LOR is known to occur due to
pharmacokinetic issues or the production of antibodies
against the drug; however, it can also be caused by a
shift in the inflammatory response pathway from TNF
signaling to non-TNF signaling. Moreover, due to their
comprehensive immunosuppressive effects, the use of
anti-TNF agents can cause severe adverse reactions,
including tuberculosis (TB), hepatitis B, pneumonia,
herpes zoster, and other infections, as well as skin
cancer, malignant lymphoma, psoriasis, lupus-like syn
drome, demyelinating disease, congestive heart failure,
and hepatotoxicity.
Although anti-TNF therapy has reduced the rate
of surgery in IBD patients, a considerable number of
patients experience a relapse of inflammation after as
[10]
they stop anti-TNF . After stopping TNF antagonist, the
[9,11]
.
12-mo relapse rate is 40% for CD and 28% for UC
Therefore, there is an urgent need for drugs with novel
mechanisms that are more effective and safer than antiTNF agents, or in particular, that can be used when antiTNF therapy is ineffective or causes an adverse reaction.
Since biological drugs have a high molecular weight,
they are inevitably delivered by injection, and their
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INTRODUCTION
Causes of inflammatory bowel disease (IBD) have not
yet been clearly elucidated, but it is known that genetic
susceptibility, altered gut microbiota, and environmental
factors are all involved. It has also been reported that
a combination of these factors causes an inappropriate
immune response, resulting in impaired intestinal
[1-3]
barrier function .
As continual research further reveals the immuno
pathogenesis of IBD, the treatment of IBD has shifted
from conventional treatments, such as aminosalicylates,
glucocorticoids, and immunomodulators (thiopurines
and methotrexate), toward the biological drugs that
[4]
target inflammation-related pathways . Anti-tumor
necrosis factor (TNF) agents were the first biologics
used to treat IBD, and the objective of IBD treatment
has shifted from controlling symptoms to changing the
progression of disease and preserving the intestinal
function. However, anti-TNF agents are not effective in
all IBD patients, and a considerable number of patients
experience relapse after stopping medication. The
pathophysiology of IBD is very complex. This means
that the most appropriate treatment method may vary
for each patient, and therefore, constant efforts are
[4]
being made to develop effective drugs . In particular,
new biologics that inhibit leukocyte trafficking to the
site of inflammation have been developed and used.
These drugs are called anti-integrin or anti-adhesion
agents, or leukocyte-trafficking inhibitors because
they block the actions of integrin, a cell surface protein
expressed by circulating immune cells and endothelial
cell adhesion molecules (CAMs), thereby selectively
preventing the intestinal recruitment of lymphocytes to
[5]
the site of inflammation . Thus, unlike anti-TNF drugs,
anti-integrin agents inhibit the interactions between
leukocytes and the intestinal vasculature, and selectively
prevent the influx of inflammatory cells, which mediate
the inflammatory process in IBD, into intestinal lesions.
In this report, we aim to discuss anti-integrin therapy,
which is currently being highlighted as a new drug
therapy for the treatment of IBD.

NEED FOR NEW DRUGS
A variety of inflammatory and anti-inflammatory cy
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Figure 1 Process of leukocyte migration through the endothelium. Leukocytes moving in the blood begin to tether and roll at a specific site of the vessel wall,
undergo activation, arrest and adhesion to the vascular endothelial cells, eventually migrate between the endothelial cells.

Leukocyte

endothelial cells, and finally undergo transendothelial
migration (Figure 1). This process of leukocytes migration
is mediated by interactions between leukocytes and
adhesion molecules expressed by endothelial cells, which
enables circulating leukocytes to migrate to the target
[12]
tissues .
Leukocytes also express CAMs on the surface, called
integrins which allow them to interact with the vascular
endothelial cells or other cells. Integrin is a heterodimeric
receptor formed from α and β subunits and is divided
into several groups depending on the structure of the α
and β subunit, and different populations of leukocytes
express different integrins. These integrins include α4β1
(found on most leukocytes), α4β7 [found specifically
on lymphocytes in the gastrointestinal (GI) tract], and
αEβ7 (found on intraepithelial T cells, dendritic cells,
[13]
mast cells or regulatory T cells) . Integrins react with
CAMs in the immunoglobulin (Ig) superfamily expressed
by other cells to induce cell adhesion; α4β1, α4β7, and
αEβ7 integrins bind to vascular cell adhesion molecule-1
(VCAM-1) on vascular endothelial cells, mucosal
addressin cell adhesion molecule-1 (MAdCAM-1) on
intestinal endothelial cells, and E-cadherin on mucosal
[14]
epithelial cells (Figure 2) .
The migration of leukocytes to the intestinal mucosa
and the recruitment of immune cells to the site of in
flammation due to increased expression of CAMs are
essential to the development and maintenance of in
testinal inflammation. Therefore, leukocyte trafficking
to the gut is central to the immunopathogenesis of IBD,
and its inhibition is recognized as an important goal in
[5]
the development of anti-IBD drugs .

αEβ7

α4β1
α4β7
Natalizumab
AJM300

Etrolizumab

Natalizumab

VCAM-1
MAdCAM-1

Vedolizumab
Abrilumab
PF-00547659

E-cadherin

Epithelial cell

Endothelial cell
Endothelial cell

Figure 2 Therapeutic targets of anti-integrin agents[14]. VCAM-1: Vascular
cellular adhesion molecule-1; MadCAM-1: Mucosal addressin cellular adhesion
molecule-1.

immunogenicity leads to infusion reactions or LOR asso
ciated with the antidrug antibody. Therefore, one aspect
of new drug development is to focus on small molecules
of less than 1 kDa that could be taken orally, thereby
increasing compliance, relatively inexpensive, and have
almost no immunogenicity, allowing them to be taken
safely on a long-term basis.

IMMUNE CELL TRAFFICKING
Innate and adaptive immune responses depend on the
trafficking of immune cells to the organ targeted by the
disease. During an inflammatory response, circulating
leukocytes migrate to the target tissues through a
homing process that takes place in several stages.
Migrating leukocytes in the bloodstream begin tethering
(capture) and rolling to a specific place, through the
activation process, arrest and adhere to vascular
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ANTI-INTEGRIN THERAPIES
Anti-integrin therapies block the action of integrins,
expressed by circulating immune cells, on endothelial
CAMs, thereby decreasing the trafficking of immune
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Table 1 Anti-integrin therapies for inflammatory bowel disease
Drug

Formula

Natalizumab
AJM300
Vedolizumab

Target

Humanized IgG4 mAb
α4-integrin
Small molecule
α4-integrin
Humanized IgG1 mAb α4β7-integrin

Abrilumab (AMG 181/MEDI 7183) Fully human IgG2 mAb α4β7-integrin
Etrolizumab

PF-00547659 (SHP647)

Humanized IgG1 mAb

β7-integrin

Fully human IgG2κ mAb MAdCAM-1

Route

Clinical studies

Summary

i.v.
Oral
i.v.

ENCORE
Phase Ⅱa
GEMINI 1
GEMINI 2
GEMINI 3
Phase Ⅱb
Phase Ⅱb
EUCALYPTUS
BERGAMOT
HICKORY
TURANDOT
OPERA

Induction and maintenance in CD
Induction in UC
Induction and maintenance in UC
Induction and maintenance in CD
Induction in CD
Induction in UC
Induction in CD
Induction in UC
Induction in CD
Induction in CD
Induction in UC
Induction in CD

s.c.
i.v./s.c.

i.v./s.c.

IgG: Immunoglobulin; mAb: Monoclonal antibody; i.v.: Intravenous; CD: Crohn’s disease; UC: Ulcerative colitis; s.c.: Subcutaneous; MAdCAM: Mucosal
addressin cell adhesion molecule.
[18]

approximately 1 case per 1000 patients . The use of
immunomodulators before natalizumab administration,
a positive test for anti-JC virus antibody, and longer
duration of natalizumab treatment are risk factors for
[19]
PML . Thus, natalizumab has been approved by the
United States. FDA only in moderate-to-severe CD
patients who did not respond to or were intolerant of
conventional treatment or TNF inhibitor therapy; it has
not been approved for use in Europe.

cells to the endothelium and suppressing the recruit
ment of inflammatory cells such as lymphocytes to in
testinal lesions. Table 1 shows the anti-integrin agents
currently approved and in use or in clinical trials.

Natalizumab

Natalizumab is a chimeric recombinant human IgG4
antibody that targets the α4 subunit in α4β7 and α4β1
integrins on leukocytes. α4β1 integrin interacts with
VCAM-1. Natalizumab was first approved by the U.S.
Food and Drug Administration (FDA) as a treatment
for multiple sclerosis, which is an autoimmune disease
of the central nervous system (CNS), and clinical trials
were conducted to test its efficacy against CD.
In the phase Ⅲ Efficacy of Natalizumab in Crohn’s
disease Response and Remission (ENCORE) trial, 509
patients with moderate-to-severe activity and elevated
C-reactive protein (CRP) (> 0.287 mg/dL) were allo
cated, in a 1:1 ratio, into groups receiving either 300
mg of natalizumab or placebo by intravenous injection
at weeks 0, 4, and 8. The primary end point, which
was the percentage of patients showing a clinical
response [defined as a decrease of at least 70 points
in CD activity index (CDAI) score] at week 8 and
sustaining this response until week 12, was higher in
the natalizumab group, at 48%, than in the placebo
[15]
group, at 32% (P < 0.001) . The percentage of
patients showing sustained clinical remission (defined
as a CDAI score under 150 points) at both week 8 and
week 12 was also higher in the natalizumab group, at
26%, than in the placebo group, at 16% (P = 0.002).
However, natalizumab prevents α4β1 integrin on leuko
cytes from binding VCAM-1 on vascular endothelial
cells in the CNS as well as in the intestines; it has been
reported that by reducing T cell trafficking to the brain,
natalizumab can affect cerebral antiviral immunity, and
in some cases, can cause a fatal brain infection called
progressive multifocal leukoencephalopathy (PML)
due to the reactivation of the John Cunningham (JC)
[16,17]
virus
. Based on clinical trial data, the risk of PML
after a mean of 17.9 mo of natalizumab treatment is

WJG|www.wjgnet.com

AJM300

Despite safety issues for natalizumab, the oral α4 integrin
antagonist AJM300 was developed and evaluated for
use in UC. A phase Ⅱa clinical trial was conducted in
Japan on 102 patients with moderately active UC, who
were intolerant or showed an inappropriate response to
mesalamine or corticosteroids; when AJM300 960 mg or
placebo was administered 3 times per day, the primary
end point, which was the rate of clinical response (defined
as a decrease of at least 3 points, and at least 30%
compared to baseline, in the complete Mayo score,
as well as a decrease of at least 1 point for the rectal
bleeding or an absolute rectal bleeding subscore of 1
point or less) at week 8, was significantly higher in the
AJM300 group, at 62.7%, than in the placebo group, at
[20]
25.5% (P = 0.0002) . Meanwhile, the clinical remission
(defined as a complete Mayo score of 0-2 points and
no subscore higher than 1 point) rate was 23.5% in
the AJM300 group and 3.9% in the placebo group (P =
0.0099), and the mucosal healing rate was 58.8% in
the AJM300 group and 29.4% in the placebo group (P
= 0.0014), both of which were significantly different. In
this clinical study, serious adverse events did not occur,
and adverse events were mild and self-limiting. However,
considering that AJM300 shares the mechanism of
natalizumab, and the number of subjects in this trial
was small, and the study period was short, there are
concerns about its practicality as a therapeutic drug.
Nevertheless, the duration of effect for AJM300 is very
short compared to that of natalizumab, and since it is an
oral formulation, there is some expectation that it may
cause fewer systemic adverse events.
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Vedolizumab

52, was 15.9% in the placebo group, 41.8% in the VDZ
every eight weeks group, and 44.8% in the VDZ every
four weeks group, which showed that the effect was
2-fold higher in the VDZ groups than in the placebo
group (P < 0.001). The durable clinical response
(response at both week 6 and 52) was 23.8% in the
placebo group, 56.6% in the VDZ every eight weeks
group, and 52.0% in the VDZ every four weeks group,
which was significantly different (P < 0.001). Similarly,
mucosal healing at week 52 was 19.8% in the placebo
group, 51.6% in the VDZ every eight weeks group,
and 56.0% in the VDZ every four weeks group, which
was also significantly different (P < 0.001). There was
no significant difference in the efficacy of VDZ between
the four-week and eight-week interval groups. Among
patients who had experienced failure with anti-TNF
therapy, the clinical remission rate was much lower
in the placebo group, at 5.3%, than in the VDZ every
eight weeks group, at 37.2%, and the VDZ every four
weeks group, at 35.0% (P < 0.001). Therefore, VDZ
demonstrated an effect against moderate-to-severe
UC at week 6 and at week 52, irrespective of previous
anti-TNF therapy. In the post-hoc analysis for the
GEMINIⅠ trial, patients were divided into those who
were naïve to TNF antagonist (464 patients) and failed
[25]
to TNF antagonist (367 patients) . The treatment
effect measured by the clinical response at week 6 was
stronger in patients who were naïve to anti-TNF therapy
[absolute difference (AD) between VDZ and placebo
26.4%] than in those who failed to anti-TNF therapy
(AD 18.1%). In the maintenance phase, the ADs in
week 52 clinical remission rates were 28.0% in patients
who were naïve to anti-TNF therapy and 29.5% in
patients who failed to anti-TNF therapy, respectively.
Even among patients who had previously experienced
failure with anti-TNF therapy, those who experienced
LOR showed a lesser effect of VDZ than those who
experienced PNR or intolerance.
The GEMINI 2 trial, consisting of 2 cohorts, analyzed
[26]
the efficacy of VDZ in active CD patients . The 368
patients in cohort 1 were randomly allocated in a 3:2
ratio, with each group receiving intravenous VDZ 300
mg or placebo at weeks 0 and 2, and evaluated at
week 6. The primary endpoint, which was the clinical
remission rate at week 6, was significantly higher in
the VDZ group, at 14.5%, than in the placebo group,
at 6.8% (P = 0.02). The other primary endpoint, the
CDAI-100 response rate (defined as a decrease of at
least 100 points in the CDAI score relative to baseline),
was higher in the VDZ group, at 31.4%, than in the
placebo group, at 25.7%; however, this difference was
not statistically significant (P = 0.23). To meet the
required sample size for the maintenance phase, an
additional 747 patients (cohort 2) were recruited for
an open-label trial, and administered VDZ by the same
method. In the maintenance phase, 461 patients who
had shown a clinical response to VDZ at week 6 which
administered either placebo, or VDZ 300 mg every four
weeks or every eight weeks. The primary endpoint in

Vedolizumab (VDZ; MLN0002) is a humanized
monoclonal IgG1 antibody against α4β7-integrin that
inhibits the adhesion of leukocytes to the endothelium
by blocking the interaction between α4β7-integrin and
MAdCAM-1 expressed on blood vessels and lymph
nodes associated with the GI tract. The main difference
between natalizumab and VDZ is that natalizumab
inhibits leukocyte trafficking in multiple organs,
including the brain, whereas VDZ acts specifically only
on gut-trophic α4β7 heterodimers, and therefore,
inhibits lymphocyte trafficking selectively in the
intestine. Although MAdCAM-1 exists rarely at the
blood-brain barrier, VDZ is known to have no effect on
[21]
CNS immunity . In a study in support of this idea,
healthy volunteers were injected VDZ and when the
cerebrospinal fluid (CSF) was tested 5 wk later, no
change was observed in CSF lymphocyte counts or
[22]
CD4:CD8 ratio following VDZ administration . In
another randomized controlled trial comparing VDZ with
a placebo, the serum antibody response to a parenteral
hepatitis B vaccine did not differ between the 2 groups,
but the response to an oral cholera vaccine showed
less antibody formation in the VDZ group compared to
the placebo group, demonstrating that while VDZ has
no effect on systemic immunity, it decreases immune
[23]
surveillance in the GI tract .
The phase Ⅲ GEMINI 1 trial, consisting of 2 cohorts,
analyzed the efficacy of VDZ in 895 moderate-tosevere UC patients who had previously received ste
[24]
roid, immunomodulator, or anti-TNF therapy . The
374 patients in cohort 1 were randomly allocated in a
ratio of 3:2, with each group receiving 2 intravenous
injections of VDZ 300 mg or placebo at week 0 and
2, and evaluated at week 6. The primary endpoint in
the induction phase, which was the clinical response
rate at week 6, was significantly higher in the VDZ
group, at 47.1%, than in the placebo group, at 25.5%
(P < 0.001). The clinical response rate at week 6 was
also significantly higher in the VDZ group than in the
placebo group among patients who had previously
experienced treatment failure with anti-TNF agents
(39.0% vs 20.6%, P = 0.01) or steroids (59.5% vs
20.0%, P < 0.001). Moreover, the clinical remission
rate at week 6 was 16.9% in the VDZ group and 5.4%
in the placebo group (P = 0.001), whereas the mucosal
healing rate at week 6 was 40.9% in the VDZ group
and 24.8% in the placebo group (P = 0.001), and
these differences were statistically significant. To meet
the required sample size for the maintenance phase,
an additional 521 patients (cohort 2) were recruited for
an open-label trial, and administered VDZ by the same
method. In the maintenance phase, the 373 patients
who achieved a clinical response with VDZ at week
6 were randomized in a 1:1:1 ratio, with each group
receiving either a placebo, or VDZ 300 mg every four
weeks, or every eight weeks. The trial lasted for a total
of 52 wk. The primary endpoint in the maintenance
phase, which was the clinical remission rate at week
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the maintenance phase, which was the clinical remission
rate at week 52, was 21.6% in the placebo group,
39.0% in the VDZ every eight weeks group, and 36.4%
in the VDZ every four weeks group, indicating that both
the VDZ every eight weeks (P < 0.001) and VDZ every
four weeks (P = 0.004) groups showed significantly
higher clinical remission rates than the placebo group.
Similarly, the CDAI-100 response rate at week 52 was
30.1% in the placebo group, 43.5% in the VDZ every
eight weeks group, and 45.5% in the VDZ every four
weeks group, indicating that the response rate was sig
nificantly higher in the VDZ every eight weeks group (P
= 0.01) and the VDZ every four weeks group (P = 0.005)
than in the placebo group. Among patients who had
previously experienced failure with anti-TNF therapy,
the remission rates at week 52 were 28.0%, 27.3%,
and 12.8% for the VDZ every eight weeks, VDZ every
four weeks, and placebo groups, respectively. This was
significantly higher in the VDZ every eight weeks group
(P = 0.01) and the VDZ every four weeks group (P =
0.02) than in the placebo group.
The GEMINI 3 trial was a phase Ⅲ randomized
controlled trial examining the efficacy and safety of VDZ
[27]
in 416 moderate-to-severe CD patients . Most of the
participants (315 patients) had previously experienced
failure with anti-TNF therapy (PNR, LOR, or intolerance).
After the injection of VDZ 300 mg at weeks 0, 2, and
6, unlike the GEMINIⅠ and Ⅱ trials, the effects of VDZ
were evaluated at week 10 as well as week 6. Among
anti-TNF-naïve patients, the clinical remission rate at
week 6 was 12.0% in the placebo group and 31.4% in
the VDZ group, which was significantly different (P =
0.012). However, among patients with previous antiTNF therapy failure, the clinical remission rate at week
6 was 12.1% in the placebo group and 15.2% in the
VDZ group, which was not a statistically significant
difference (P = 0.433), whereas the clinical remission
rate at week 10 was significantly higher in the VDZ
group, at 26.6%, than in the placebo group, at 12.1%
(P = 0.001). Meanwhile, in patients with previous antiTNF therapy failure, the CDAI-100 response rates at
weeks 6 and 10 were 22.3% and 24.8%, respectively,
in the placebo group, but were significantly higher in
the VDZ group, at 39.2% and 46.8% (P = 0.001 and P
< 0.001, respectively). These results show that patients
who experience anti-TNF therapy failure take longer to
show an effect from VDZ than anti-TNF-naïve patients.
Notably, among the subjects in this trial, patients who
had experienced anti-TNF therapy failure had a longer
disease duration and more structural damage than
anti-TNF-naïve patients, which could have affected the
clinical effects of VDZ. In the post-hoc analyses for the
GEMINI 2 and 3 trials, for patients in the VDZ group, the
clinical remission rate at week 52 was 48.9% in patients
who were naïve to anti-TNF therapy and 27.7% in
patients who had experienced anti-TNF therapy failure,
whereas the remission rates in the placebo group were
[28]
26.8% and 12.8%, respectively . This shows that the
clinical remission rates are higher in the VDZ group than

WJG|www.wjgnet.com

in the placebo group, and that this effect is larger when
patients have not previously been exposed to anti-TNF
therapy.
Vedolizumab was approved by the FDA and the Euro
pean Medicines Agency, for the treatment of moderate to
severe ulcerative colitis and CD adult patients which are
not responding to one or more conventional treatment
such as steroids, immunosuppressive agents, or TNF
antagonists. The results of the VDZ clinical trials showed
different treatment effects in UC and CD. There are
several theories to explain why the clinical effect of
inhibiting leukocyte trafficking in CD appeared later
than that in UC. CD can show systemic manifestations
and affect the whole GI tract from the oral cavity to the
anus, showing inflammation in all layers of the intestine;
conversely, UC is limited to the colonic mucosa, which
could explain the discrepancy in the treatment response.
Recently, a study on IBD patients and a humanized
mouse model found that VDZ treatment in CD reduced
the expression of α4β1 in the peripheral blood and
increased the expression of α4β1 in the intestine,
suggesting that in CD, the VDZ-mediated inhibition of
α4β7 could have been circumvented by homing to the
[29]
ileum via α4β1 on effector T cells . Thus, further indepth research is required to better understand the
pharmacokinetics and pharmacodynamics of VDZ in CD.
The GEMINI long-term safety (LTS) study examined
[30,31]
the long-term safety and efficacy of VDZ
. Among
patients in the phase Ⅱ trial C13004, the GEMINI 1 trial,
and VDZ-naïve UC patients who showed a response to
VDZ at week 6 were switched to an open-label study
and administered VDZ 300 mg continually at four-week
[30]
intervals for 152 wk . In an interim report on the
efficacy of VDZ, the remission rates after 104 and 152
wk were 88% (120/136) and 96% (70/73), respectively,
demonstrating a high maintenance of remission. Among
patients who dropped out of the VDZ maintenance
treatment at eight-week intervals before 52 wk in
GEMINIⅠ trial (n = 32), increased dosing frequency
to every four weeks in GEMINI LTS improved clinical
responses and remission rates from 19% and 6% to
41% and 28%, after 52 wk of GEMINI LTS, respectively.
Similarly, among CD patients who had participated in
the C13004, GEMINI 2, or GEMINI 3 trial, or were VDZnaïve, those who showed a response to VDZ at week 6,
when switched to an open-label study and monitored for
152 wk while receiving VDZ every four weeks, showed
remission rates after 104 and 152 wk of 83% (100/120)
[31]
and 89% (62/70), respectively . Among patients
who dropped out of the VDZ maintenance treatment at
eight-week intervals before 52 wk in GEMINI 2 trial (n =
57), increased dosing frequency to every four weeks in
GEMINI LTS improved clinical responses and remission
rates from 39% and 4% to 47% and 32%, after 52
wk of GEMINI LTS, respectively. Therefore, for patients
who show a response to VDZ every eight weeks in the
induction phase, but show LOR in the maintenance
phase, increasing the dosing frequency to every four
weeks could produce a response again.
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To examine mucosal and histological healing
when VDZ was administered, prospective surveillance
colonoscopy was performed in patients registered for
[32]
the GEMINI LTS trial . The follow-up period was over
1 year (1.1-6.1 years, median 3.2 years), the rate of
mucosal healing with a Mayo score of 1 or less was 50%
(17/34) for UC and 29% (7/24) for ulcer-free mucosal
healing in CD patients. Histological healing with mucosal
healing in UC and CD patients was 32% (11/34) and
21% (5/24), respectively.
The VERSIFY study was examined endoscopic mu
cosal healing at week 26 after VDZ treatment in 101
moderate-to-severe CD patients who had previously
experienced failure with corticosteroids, immunomodu
lators, and/or anti-TNF agents. The endoscopic remission
[simple endoscopic score for CD (SES-CD) ≤ 4] rate
was 12% overall, 20% for patients who were naïve to
anti-TNF therapy (n = 46), and 6% for patients who
had previously experienced anti-TNF therapy failure (n
[33]
= 55) . The endoscopic response (SES-CD decrease
of at least 50%) and complete endoscopic healing (no
ulcerations) rates were, respectively, 25% and 15%
overall, 28% and 24% for patients who were naïve to
anti-TNF therapy, and 22% and 7% for patients who
had failed at anti-TNF therapy. Thus, VDZ is effective at
inducing endoscopic remission and healing in refractory
CD patients, and the rates of endoscopic remission and
healing are higher in anti-TNF-naïve patients than in
those who have experienced anti-TNF therapy failure.
The US VICTORY Consortium provides data relating
to VDZ from real-world experience; among 212 mode
rate-to-severe CD patients, 90% had exposed to antiTNF therapy, and the median follow-up duration was
[34]
39 wk . In responders, the median time to respond
to VDZ was 19 wk. After 6, 12, and 18 mo of VDZ
therapy, patients showed clinical remission rates of 18%,
35%, and 54%, respectively, and after 6 and 12 mo of
treatment, showed cumulative mucosal healing rates
of 20% and 63%, respectively, and cumulative deep
remission (clinical remission and mucosal healing) rates
of 14% and 26%, respectively. Higher disease activity,
active perianal disease, smoking history, and prior TNF
antagonist exposure were all factors that decreased the
effectiveness of VDZ.
In a German cohort study including 115 active UC
patients and 97 active CD patients, only 24.3% of UC
patients and 5.2% of CD patients were naïve to TNF
[35]
antagonist . When these patients were treated with
VDZ and monitored for 14 wk, at week 14, 23.5% of
UC patients and 23.7% of CD patients achieved clinical
remission, 57.4% of UC patients and 60.8% of CD
patients showed a clinical response, and steroid-free
remission was observed in 19.1% of UC patients and
19.6% of CD patients. Serum CRP and calprotectin
levels were measured at weeks 0, 6, and 14; patients
are showed decreased CRP levels, but this was not
statistically significant, whereas calprotectin levels
decreased significantly.
In the GETAID Cohort Data from France, the effects
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of VDZ treatment were analyzed in 121 UC patients and
173 CD patients who had failed with anti-TNF therapy. At
week 6, the clinical remission rates were 32% and 31%,
the steroid-free clinical remission rates were 21% and
19%, and the clinical response rates were 41% and 57%
[36]
in the UC and CD patients, respectively . At week 14,
the clinical remission rates for UC and CD patients were
respectively 39% and 36%, the steroid-free remission
rates were 36% and 31%, and the clinical response
rates were 57% and 64%, demonstrating that VDZ is
effective for both UC and CD. The fact that a superior
treatment response was observed at week 14 compared
to week 6 re-confirms that it takes time for the effects
of treatment to become apparent. When patients were
monitored for 1 year, steroid-free remission at week
22 was 40% for UC patients and 34% for CD patients,
indicating that remission rates gradually increased for
both diseases, and that UC patients achieved steroidfree remission sooner than CD patients.
In summary, real-world data for VDZ treatment
were similar to results of randomized controlled studies.
In particular, it takes considerable time before the
maximal effects of VDZ therapy can be observed, and
corticosteroid treatment may be required during this
period. The results of a network meta-analysis show that
VDZ is more effective overall than anti-TNF therapy in the
[37]
maintenance phase . Thus, the effect of VDZ, once it
becomes apparent, is maintained more strongly, and this
sustained effect is considered its greatest advantage. In
addition, for patients showing PNR, LOR, or intolerance
to anti-TNF therapy, it is worth considering VDZ as a
secondary treatment (Table 2).
Because VDZ acts selectively on the intestine, it
causes relatively little systemic immunosuppression,
and this is expected to result in fewer adverse events.
In the GEMINI 1 and 2 trials, the most commonly
reported adverse reactions to VDZ (incidence ≥ 5%)
were nausea, nasopharyngitis, upper respiratory tract
infection, arthralgia, fever, fatigue, headache, and
[24,26]
cough
. In safety data from the 6 VDZ clinical trials
(placebo-controlled trials C13002, GEMINI 1, 2, and 3,
and open-label trials C13004 and GEMINI LTS), VDZ
showed no significant difference from the placebo in
[38]
overall adverse reactions . In particular, the exposureadjusted incidence rates of infections and serious
infections, which is a problem in anti-TNF therapy,
were 63.5/100 person-years (PYs) and 4.3/100 PYs in
patients receiving VDZ, respectively, and 82.9/100 PYs
and 3.8/100 PYs in the placebo group, respectively.
However, the rates of gastroenteritis and Clostridium
difficile infection were low but higher in VDZ-treated
patients (4.0/100 PYs and 0.4/100 PYs, respectively)
than those in the placebo group (1.4/100 PYs and
0.0/100 PYs, respectively), and further studies will be
required to determine whether these results are due to
gut-selective immune suppression by VDZ. In safety
data from the 6 VDZ clinical trials, 18 patients developed
malignancy, including GI cancer (6 patients), skin cancer
(5 patients), lung cancer (2 patients), genitourinary
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Table 2 Comparison of properties of anti-tumor necrosis factor and gut-specific anti-integrin therapy

Mechanism of action
Available agents

Therapeutic efficacy
Side effects
Immunogenicity

Anti-TNF therapy

Gut-specific anti-integrin therapy

TNF-α inhibitor
Infliximab (UC, CD)
Adalimumab (UC, CD)
Certolizumab pegol (CD)
Golimumab (UC)
Frequent loss of response during maintenance therapy
Infections, reactivation of latent tuberculosis, potential risk of lymphoma
Measure the ADA if available
Add immunomodulator (infliximab)

α4β7-integrin inhibitor
Vedolizumab (UC, CD)

Modest effect on induction therapy for CD
Nasopharyngitis, arthralgia, headache, nausea
No significant immunogenicity

TNF: Tumor necrosis factor; UC: Ulcerative colitis; CD: Crohn’s disease; ADA: Antidrug antibodies.

cancer (2 patients), breast cancer (2 patients), and
B cell lymphoma (1 patient). Colon cancer (0.1/100
PYs) was the most common type of GI cancer, but its
incidence was lower than that observed in IBD patients
in the HealthCore Integrated Research Database
[38,39]
(2.1/1000 PYs; 95%CI: 1.3-3.2)
. Infusion-related
reactions were reported with a low incidence of less
[38]
than 5% in patients who received VDZ . VDZ does
not affect α4β1-related nervous system leukocyte
trafficking, and no cases of PML were observed in the
clinical trials. Therefore, VDZ can be considered as a
primary biological drug in elderly patients with a high
risk of opportunistic infections or cancer and in young
male patients at risk of hepatosplenic T cell lymphoma.
Especially in countries with a high prevalence of TB, such
as Korea, China, and India, the risk of TB needs to be
considered when selecting a therapeutic drug. VDZ is
expected to be a very low-risk drug in this regard, with
only 4 TB cases out of approximately 3000 patients who
received VDZ (0.1%). Another advantage of VDZ is that
it can be used even in the presence of comorbidities that
contraindicate anti-TNF therapy, such as demyelinating
disease, congestive heart failure, and lymphoma.
Nevertheless, due to the gut selectivity of VDZ, it
may not be expected to be effective in patients with
extraintestinal symptoms. Recently, a case of CD invol
ving the pleura and lungs after 3 doses of VDZ has been
[40]
reported . After isolating peripheral blood mononuclear
cells from the patient, flow cytometry revealed an upre
gulation of β1 integrin, which is required for homing
of lymphocytes to the lungs, and the condition of the
patient improved after prednisolone treatment. This
shows that the shift in integrin expression triggered by
VDZ can cause immune cells to migrate to organs other
than the gut, thereby increasing the risk of extraintestinal
autoimmune manifestations in CD.
Anti-VDZ antibodies (AVAs) were detected in 56 out
of 1434 patients (4%) who were treated with VDZ up to
week 52 in the GEMINI 1 and 2 trials, but of these, only
9 patients (0.6%) continued to show AVA positivity, and
[38]
33 patients (2.6%) developed neutralizing antibodies .
In the GEMINI LTS trial, the immunogenicity rate did
not increase over time. When VDZ was administered
in combination with immunosuppressants at baseline,
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the AVA positivity rate was 3%, which was 1% lower
than the AVA positivity rate of 4%. However, these
measurements were taken when the patients had a
high serum drug concentration, which could have inter
fered with the assay. Therefore, VDZ seems to have
low immunogenicity and could be used without immu
nosuppressants; however, further research is required.
VDZ may be expected to have a positive effect on
fistula closure rate in CD. The phase IV ENTERPRISE
trial (NCT02630966), which is currently underway,
focuses on fistula healing at week 30 after 22 wk of VDZ
medication in patients with fistulizing CD.
Research on combination therapy has so far been
limited to case reports. One report found that VDZ
+ etanercept, the soluble TNF receptor, combination
therapy is effective at controlling severe pouchitis and
spondylarthritis that developed in a patient with UC; one
UC patient who showed no response to treatment with
methotrexate, adalimumab, infliximab, azathioprine,
cyclosporine A, or golimumab showed clinical remission
and mucosal healing when treated with a combination of
[41,42]
VDZ + certolizumab pegol and monitored for 21 mo
.
These reports indicate that combination therapy using
VDZ and an anti-TNF agent can provide additional clinical
benefits, and an open-label study is currently underway
to examine the effects of three-drug combination therapy
using VDZ, adalimumab, and methotrexate in high-risk
CD patients (NCT02764762).
Recently, a study was published on biomarkers that
[43]
can predict response to VDZ . Using VDZ labeled
with fluorescein isothiocyanate, α4β7-expressing cells
were detected by confocal laser endomicroscopy;
clinical response and endoscopic remission to VDZ were
observed in patients who showed pericryptal α4β7+ cells
in the mucosa, whereas patients without α4β7+ cells did
not respond to VDZ.

Abrilumab

Abrilumab (AMG 181/MEDI 7183) is a fully human
monoclonal IgG2 antibody against α4β7 integrin that
has recently been used in several clinical trials.
In a phase Ⅱb study to evaluate the efficacy and
safety of abrilumab in 354 moderate-to-severe UC pa
tients who showed an inappropriate response or LOR
to anti-TNFs, immunomodulators, or corticosteroid

1875

May 7, 2018|Volume 24|Issue 17|

Park SC et al . Anti-integrin therapy for IBD
therapy, patients were divided into a placebo group,
groups receiving subcutaneous abrilumab 7, 21, or 70
mg at weeks 0, 2, and 4, followed by its administration
once every four weeks, and a group receiving a single
[44]
subcutaneous 210 mg dose of abrilumab . The primary
endpoint, which was remission rate at week 8, was
1.6%, 2.9%, 13.5%, and 13.4% in the abrilumab 7 mg,
21 mg, 70 mg, and 210 mg groups, respectively, and
was 4.4% in the placebo group; the abrilumab 70 mg
group (P = 0.021) and 210 mg group (P = 0.030) both
showed a significantly higher remission rate than the
placebo group. Abrilumab increased α4β7-high central
memory CD4+ T cell counts in the peripheral blood, and
high trough abrilumab concentrations were associated
with increased remission rate. No PML or severe
adverse events were observed in the abrilumab groups
through week 24 and no patients developed neutralizing
antibodies to abrilumab. Thus, abrilumab showed
advantageous pharmacokinetics, pharmacodynamics,
very low immunogenicity, and an acceptable safety
profile; further results are expected in the future.
A phase Ⅱb trial was conducted to evaluate the
efficacy and safety of abrilumab in 249 patients with
moderate-to-severe CD who showed evidence of active
inflammation and an inappropriate response, LOR,
or intolerance to immunosuppressants, anti-TNFs, or
[45]
corticosteroid therapy . Patients were divided into a
placebo group and groups receiving abrilumab 21 mg
or 70 mg at weeks 0, 2, and 4, followed by once every
four weeks, and a group receiving a single 210 mg dose
of abrilumab. The primary endpoint, which was CDAI
remission (CDAI score of < 150 points) rate at week
8, was 23.1%, 14.4%, and 21.9% in the abrilumab
21 mg, 70 mg, and 210 mg groups, respectively, and
12.8% in the placebo group; there were no statistically
significant differences between the abrilumab groups
and the placebo group. However, among patients who
had previously experienced anti-TNF treatment failure,
CDAI remission rates at week 12 were 22.9%, 17.4%,
and 24.8% in the abrilumab 21 mg, 70 mg, and 210
mg groups, respectively, which were all significantly
higher than the remission rate of 8.2% in the placebo
group (P < 0.01). Also, in patients with prior anti-TNF
failure, the CDAI response (decrease of at least 100
points in CDAI score compared to baseline) rates at
week 12 in the abrilumab 21 mg, 70 mg, and 210 mg
groups were 30.0%, 39.4%, and 37.4%, respectively,
and these values in the abrilumab 70 mg and 210 mg
groups were significantly higher than the response rate
of 14.2% in the placebo group (P < 0.01). Adverse
events up to week 24 were the same in the abrilumab
groups and the placebo group, and there were no cases
of PML or death in any of the abrilumab groups. Thus,
in CD, although abrilumab did not show a significant
improvement in the primary endpoint, it could show
useful effects.

IgG1 antibody against the β7 subunit of α4β7 and αEβ7
that blocks not only the interaction between α4β7 and
MAdCAM-1, but also the interaction between αEβ7 and
E-cadherin expressed mostly by epithelial cells. Thus,
etrolizumab suppresses the trafficking of lymphocytes
into the gut and the retention of lymphocytes in the
intraepithelial compartment.
The phase Ⅱ EUCALYPTUS induction study was
conducted on 124 moderate-to-severe UC patients
[46]
who showed no response to conventional therapy .
Patients were randomly allocated in a 1:1:1 ratio into
a placebo group, a group administered subcutaneous
etrolizumab 100 mg at weeks 0, 4, and 8 (and placebo
at week 2), and a group administered a loading dose
(LD) of subcutaneous etrolizumab 420 mg, followed
by subcutaneous doses of 300 mg at weeks 2, 4, and
8. The primary endpoint, which was clinical remission
rate at week 10, was 0% in the placebo group, 20.5%
in the etrolizumab 100 mg group (P = 0.004), and
10.3% in the etrolizumab 300 mg plus LD group (P =
0.048); the clinical remission rate was higher in the
etrolizumab groups than in the placebo group. In a
subgroup analysis, among anti-TNF-naïve patients,
the clinical remission rates in the etrolizumab 100 mg
group and the etrolizumab 300 mg plus LD group were
44% and 25%, respectively; however, among patients
who had not responded to anti-TNF therapy, the clinical
remission rates were 5% and 4%. Although there were
no cases of severe infection in the etrolizumab-treated
groups, and there was no significant difference in the
rate of adverse reactions sufficient to stop medication
in the three groups, influenza-like illness (7% vs 0%
and 2%) arthralgia (15% vs 5% and 9%), and rash
(7% vs 3% and 2%) were observed more frequently
in the etrolizumab 100 mg group than the etrolizumab
300 mg plus LD group or the placebo group. However,
these adverse events were all mild or moderate,
demonstrating that etrolizumab is safe and tolerable.
One notable aspect of this study is that when quan
titative PCR and immunohistochemistry were used to
measure the number of αE gene (ITGAE)-expressing
and αE-positive cells in the colonic mucosa, higher
αE expression was associated with a higher rate of
clinical remission at week 10 in patients treated with
etrolizumab, suggesting that αE expression could be
[46]
used as a biomarker in etrolizumab treatment . The
subsequent study was conducted on colon tissues
taken by biopsies from the UC patients in this phase
Ⅱ trial, as well as the patients with UC and a control
[47]
group without IBD in an observational study . Here,
the mRNA for granzyme A (GZMA), a serine protease
that promotes cell migration and is associated with the
secretion of inflammatory cytokines such as IL-1β and
TNF-α, showed high expression in colonic CD4+ integrin
αE+ cells; higher levels of GZMA mRNA or ITGAE mRNA
were associated with a higher likelihood of responding
to etrolizumab, and their expression after etrolizumab
treatment decreased significantly by 40%-80%.
Currently, there are 5 ongoing phase Ⅲ randomized

Etrolizumab

Etrolizumab (rhuMAb β7) is a humanized monoclonal
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controlled trials (HIBISCUSⅠ, HIBISCUS Ⅱ, GARDENIA,
LAUREL, and HICKORY) and 1 rollover open-label
extension trial (COTTONWOOD) on UC.
The phase Ⅲ BERGAMOT trial aimed to evaluate
the safety and efficacy of etrolizumab in 300 moderateto-severe CD patients who were previously refractory
or intolerant to anti-TNFs, immunomodulators, and/or
[48]
corticosteroid therapy . The patients were randomly
allocated in a ratio of 1:2:2 into a placebo group, a group
receiving subcutaneous etrolizumab 105 mg every four
weeks, and a group receiving subcutaneous etrolizumab
210 mg at weeks 0, 2, 4, 8, and 12. The symptomatic
remission (abdominal pain ≤ 1 and unweighted stool
frequency ≤ 3) rates at week 6 were 15.0% and 25.6%
in the etrolizumab 105 mg and etrolizumab 210 mg
groups, respectively, which were higher than the rate of
8.5% in the placebo group. Similarly, the symptomatic
remission rates at week 10 were higher in the etroli
zumab 105 mg and etrolizumab 210 mg groups, at
15.8% and 27.3%, than the placebo group, at 8.5%, and
the symptomatic remission rates at week 14 were still
higher in the etrolizumab 105 mg and 210 mg groups, at
20.8% and 24.8%, than in the placebo group, at 11.9%.
The endoscopic improvement (decrease of at least 50%
in SES-CD compared to baseline) rates at week 14 were
also higher in the etrolizumab 105 mg and 210 mg
groups, at 21.0% and 17.4%, than in the placebo group,
at 3.4%. There were no significant differences between
the placebo group and the etrolizumab groups in adverse
events. Thus, etrolizumab showed a rapid effect at
week 6 in the treatment of moderate-to-severe CD, and
research is underway investigating the maintenance
phase.
The phase Ⅲ HICKORY open-label induction trial
aimed to investigate the efficacy of etrolizumab in 130
moderate-to-severe UC patients who showed intolerance
[49]
or no response to anti-TNFs . After patients were
administered etrolizumab 105 mg by subcutaneous
injections for 14 wk, at four-week intervals, the clinical
response and remission rates at week 14 were 50.8%
and 12.3%, respectively, and 43.9% of patients receiving
etrolizumab showed an endoscopic improvement, repre
sented by a decrease of at least 1 point in endoscopy
score compared to baseline. HICKORY including double
blind induction phase and maintenance phase is currently
ongoing (NCT02100696).
αEβ7 and α4β7 are differentially expressed in T
lymphocyte effector subsets in the peripheral blood and
intestines of IBD patients; T cell receptor stimulation and
transforming growth factor-β treatment increased the
[50]
expression of αEβ7, especially in CD8+ lymphocytes .
When used in a humanized mouse model of colitis,
etrolizumab surrogate antibody decreased the accu
mulation of CD8+ and CD4+ Th9 cells in the intestine
more strongly than VDZ; this seems to be because
etrolizumab had an additional inhibitory effect on the
[50]
αEβ7-mediated retention of lymphocytes .
If β7 integrin is blocked, it could reduce gut speci
ficity; this is because αEβ7 is expressed by T cells in
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other tissues as well as in the intestines; therefore,
[51]
problems can arise with the control of local infection .
Therefore, in the ongoing phase Ⅲ trials, it is important
to determine whether latent infection is a significant
adverse effect of etrolizumab.

PF-00547659

PF-00547659 (SHP647) is a fully human monoclonal
IgG2κ antibody targeting MAdCAM-1, an intestinal
endothelial CAM that binds α4β7 integrin on lymphocytes.
This is another strategy for inhibiting leukocyte adhesion
by blocking the endothelial CAM from binding to the
integrin ligand.
The phase Ⅱ TURANDOT trial analyzed 357 mode
rate-to-severe UC patients who had either shown failure
[52]
or intolerance for at least one conventional therapy .
PF-00547569 was administered every four weeks by
subcutaneous injection at either one of the 4 different
doses (7.5, 22.5, 75, or 225 mg) and the outcomes
were compared with a placebo. The primary endpoint,
which was clinical remission rate at week 12, was 2.7%
in the placebo group, 11.3% in the PF-00547569 7.5
mg group (P = 0.0425), 16.7% in the 22.5 mg group
(P = 0.0099), 15.5% in the 75 mg group (P = 0.0119),
and 5.7% in the 225 mg group (P = 0.1803), indicating
that the remission rate was significantly higher in the
PF-00547569 7.5 mg, 22.5 mg, and 75 mg groups than
in the placebo group, and the efficacy was the highest
in the 22.5 mg and 75 groups. The mucosal healing
rate at week 12 was 8.2% in the placebo group, 15.5%
in the 7.5 mg group (P = 0.0099), 27.8% in the 22.5
mg group (P = 0.0038), 25.4% in the 75 mg group
(P = 0.0080), and 14.3% in the 225 mg group (P =
0.0099), showing the highest value in the PF-00547569
22.5 mg and 75 mg groups. In a subgroup analysis,
among patients experiencing anti-TNF therapy failure,
the remission rate at week 12 was 0% in the placebo
group, 7.3% in the 7.5 mg group (P = 0.0425), 9.8%
in the 22.5 mg group (P = 0.0099), 9.8% in the 75 mg
group (P = 0.0119), and 2.5% in the 225 mg group
(P = 0.1803), showing significantly higher values than
the placebo group in the PF-00547569 7.5 mg, 22.5
mg, and 75 mg groups. The reason that the clinical
effect of PF-00547659 at the highest dose decreased
may be because of study design or the depletion of the
anti-inflammatory regulatory T cells to the intestine,
[53]
and further research is needed . There were no
significant differences between the placebo group and
the PF-00547569 groups in the frequency of adverse
events, and there were no cases of severe infection or
PML. When GI side effects were investigated considering
the gut selectivity of PF-00547659, Clostridium difficile
infection, anal abscess and anal fistula were observed
in patients treated with PF-00547659 and one patient
was diagnosed with adenocarcinoma of colon during the
study period. Therefore, special attention should be paid
to GI complications in the treatment of PF-00547659,
and additional data is necessary to establish its safety. A
large-scale phase Ⅲ clinical trial is currently underway in
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In the future, clinical trials of anti-integrin drugs are
expected to demonstrate their clinical efficacy, their place
in the treatment of IBD, and their associated adverse
effects. This will widen the range of drugs available
to physicians and patients for treating IBD, and is an
important step toward truly personalized treatment.

patients with UC (NCT03259334).
The phase Ⅱ OPERA trial aimed to evaluate the
efficacy and safety of PF-00547569 in 265 moderateto-severe CD patients who had previously shown no
response or intolerance for anti-TNFs and/or immu
[54]
nosuppressants . Patients were randomly allocated, in
a 1:1:1:1 ratio, to a placebo group and groups receiving
PF-00547569 at either one of the 3 doses (22.5, 75, or
225 mg). The CDAI-70 response rates at week 8 showed
no significant differences, at 47.7% in the placebo group
and 52.7%, 60.1%, and 62.7% in the PF-00547569
22.5, 75, and 225 mg groups, respectively. Similarly,
the CDAI-70 response rates at week 12 also showed no
significant differences, at 58.6% in the placebo group
and 62.8%, 64.7%, and 57.5% in the PF-00547569
22.5, 75, and 225 mg groups, respectively. However,
among patients with high baseline CRP levels (> 5 mg/dL
or > 18.8 mg/dL), the CDAI remission rates at week 8 or
12 were higher in the PF-00547569 groups than in the
placebo group. Moreover, in the PF-00547569 groups,
soluble MAdCAM level decreased significantly at week 2
in a dose-dependent manner and circulating β7+ CD4+
central memory T lymphocytes increased at weeks 8 and
12. Therefore, although the high clinical response rate in
the placebo group indicated that there was no significant
difference between the PF-00547569 groups and the
placebo group, PF-00547569 seems to be effective in
patients with active inflammation.
Given the clinical success of drugs that block α4β7
integrin, antibodies against MAdCAM-1 should produce
a similar clinical effect. However, this is not reflected
in the study results because α4β7 not only binds
MAdCAM-1, but also has epitopes for binding VCAM-1
and fibronectin, though it is known that VDZ does not
[55]
affect the adhesion of α4β7 to VCAM-1 .
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